Atlas Trials

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Clinical trial NCT02881567 · TERMINATED

Trial details

NCT number
NCT02881567
Sponsor
Biogen
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Relapsing-Remitting Multiple Sclerosis (RRMS)
Start date
2017-04-18
Primary completion
2018-09-12
Enrollment
41

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.